9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Estimated reading time: < 1 min

Condition: Tumors With CDK4/6 Pathway Activation

Estimated Enrollment: 106

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments,  Clinical Benefit Rate (CBR) of ≥ 16 Weeks FAS,  Overall Response Rate (ORR) ≥ 16 Weeks. FAS, Progression Free Survival (PFS)

Interventions: LEE011,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 17, 2018

Completion Date: January 17, 2018

Last  Posted Date: July 18, 2019

Location: University of Alabama at Birmingham, Birmingham, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT02187783

Was this article helpful?
Dislike 0